Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CardioVascular and Interventional Radiology
Erschienen in: CardioVascular and Interventional Radiology 1/2011

01.02.2011 | Review

Transcatheter Arterial Chemoembolization for Liver Cancer: Is It Time to Distinguish Conventional from Drug-Eluting Chemoembolization?

verfasst von: Eleni Liapi, Jean-Francois H. Geschwind

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Conventional transcatheter arterial chemoembolization and chemoembolization with drug-eluting beads are increasingly being performed interchangeably in many institutions throughout the world. As both therapies continue to being tested in many phase II and III studies and in combination with other therapies, especially targeted agents, for treatment of primary and metastatic liver cancer, it is imperative to review their current status and evaluate their impact on patient survival. This review critically assesses patient selection, indications, contraindications, techniques, materials, safety, and clinical outcomes of patients treated with conventional chemoembolization and chemoembolization with drug-eluting beads.
Literatur
1.
Roche A, Girish B, de Baere T et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13:136PubMed
2.
3.
Geschwind JFH (2002) Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol 13:991–994CrossRefPubMed
4.
Aoki T, Imamura H, Hasegawa K et al (2004) Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 139:766–774CrossRefPubMed
5.
Arii S, Yamaoka Y, Futagawa S et al (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224–1229CrossRefPubMed
6.
Livraghi T, Meloni F, Morabito A et al (2004) Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl 10(2 suppl 1):S98–S106CrossRefPubMed
7.
Peng ZW, Chen MS, Liang HH et al (2010) A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 36:257–263PubMed
8.
Shibata T, Isoda H, Hirokawa Y et al (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252:905–913CrossRefPubMed
9.
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMed
10.
Veltri A, Moretto P, Doriguzzi A et al (2006) Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 16:661–669CrossRefPubMed
11.
Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361PubMed
12.
Buijs M, Kamel IR, Vossen JA et al (2007) Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 18:957–963CrossRefPubMed
13.
Liapi E, Geschwind JF, Vossen JA et al (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 190:67–73CrossRefPubMed
14.
Vogl TJ, Gruber T, Balzer JO et al (2009) Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 250:281–289CrossRefPubMed
15.
Vogl TJ, Naguib NN, Nour-Eldin NE et al (2010) Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 20:173–180CrossRefPubMed
16.
Vossen JA, Kamel IR, Buijs M et al (2008) Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr 32(3):347–352CrossRefPubMed
17.
Aliberti C, Tilli M, Benea G, Fiorentini G (2006) Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 26(5B):3793–3795PubMed
18.
de Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855–861CrossRefPubMed
19.
Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616–623CrossRefPubMed
20.
Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52CrossRefPubMed
21.
Malagari K, Chatzimichael K, Alexopoulou E et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31:269–280CrossRefPubMed
22.
Martin RC, Robbins K, Tomalty D et al (2009) Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7:80CrossRefPubMed
23.
Reyes DK, Vossen JA, Kamel IR et al (2009) Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 15:526–532CrossRefPubMed
24.
Georgiades CS, Liapi E, Frangakis C et al (2006) Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 17:1619–1624CrossRefPubMed
25.
Huo TI, Lee PC, Huang YH et al (2006) The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol 40:543–550CrossRefPubMed
26.
Georgiades CS, Hong K, D’Angelo et al (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16:1653–1659PubMed
27.
Okamura J, Kawai S, Ogawa M et al (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of L-TAE with Farmorubicin and L-TAE with Adriamycin (second cooperative study). Cancer Chemother Pharmacol (Historical Archive) 31:S20
28.
Geschwind JF, Ramsey DE, van der Wal BC et al (2003) Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 26:111–117CrossRefPubMed
29.
Bhattacharya S, Dhillon AP, Winslet MC et al (1996) Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 73:877–881PubMed
30.
Bhattacharya S, Novell JR, Winslet MC, Hobbs KE (1994) Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 81:1563–1571CrossRefPubMed
31.
Terayama N, Matsui O, Gabata T et al (2001) Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol 24:383–387CrossRefPubMed
32.
Tancredi T, McCuskey PA, Kan Z et al (1999) Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents. Radiology 211:177–181PubMed
33.
Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40PubMed
34.
Cheng HY, Shou Y, Wang X et al (2004) Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 10:2753–2755PubMed
35.
Mondazzi L, Bottelli R, Brambilla G et al (1994) Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 19:1115–1123CrossRefPubMed
36.
Nakao N, Uchida H, Kamino K et al (1992) Effectiveness of lipiodol in transcatheter arterial embolization of hepatocellular carcinoma. Cancer Chemother Pharmacol 31(suppl):S72–S76CrossRefPubMed
37.
Tadavarthy SM, Knight L, Ovitt TW et al (1974) Therapeutic transcatheter arterial embolization. Radiology 112:13–16PubMed
38.
Link DP, Strandberg JD, Virmani R et al (1996) Histopathologic appearance of arterial occlusions with hydrogel and polyvinyl alcohol embolic material in domestic swine. J Vasc Interv Radiol 7:897–905CrossRefPubMed
39.
Hong K, Kobeiter H, Georgiades CS et al (2005) Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 16:1711–1717PubMed
40.
Laurent A (2007) Microspheres and nonspherical particles for embolization. Tech Vasc Interv Radiol 10:248–256CrossRefPubMed
41.
Vallee J-N, Lo D, Guillevin R et al (2003) In vitro study of the compatibility of tris-acryl gelatin microspheres with various chemotherapeutic agents. J Vasc Interv Radiol 14:621–628PubMed
42.
Siskin GP, Dowling K, Virmani R et al (2003) Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. J Vasc Interv Radiol 14:89–98PubMed
43.
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342CrossRefPubMed
44.
Lewis A, Gonzalez M, Leppard S et al (2007) Doxorubicin eluting beads. 1. Effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 18:1691–1699CrossRefPubMed
45.
Lewis AL, Taylor RR, Hall B et al (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17:1335–1343CrossRefPubMed
46.
Tang Y, Taylor RR, Gonzalez MV et al (2006) Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Controlled Release 116:e55–e56CrossRef
47.
Taylor RR, Tang Y, Gonzalez MV et al (2007) Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharmaceut Sci 30:7–14CrossRef
48.
de Luis E, Bilbao J, de Ciércoles J et al (2008) In vivo evaluation of a new embolic spherical particle (hepasphere) in a kidney animal model. Cardiovasc Intervent Radiol 31(2):367–376CrossRefPubMed
49.
Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 33:512–519CrossRefPubMed
50.
Poon RT, Tso WK, Pang RW et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108CrossRefPubMed
51.
Jaeger HJ, Mehring UM, Castaneda F et al (1996) Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 19:388–396CrossRefPubMed
52.
Liapi E, Georgiades CC, Hong K et al (2007) Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol 10:2–11CrossRefPubMed
53.
Geschwind JF, Khwaja A, Hong K (2005) New intraarterial drug delivery system: pharmacokinetics and tumor response in an animal model of liver cancer. In: 2005 ASCO annual meeting, Orlando, FL
54.
Leung DA, Goin JE, Sickles C et al (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326CrossRefPubMed
55.
Brown KT (2004) fatal pulmonary complications after arterial embolization with 40–120-μm tris-acryl gelatin microspheres. J Vasc Interv Radiol 15(2 Part 1):197–200
56.
Miyayama S, Yamashiro M, Okuda M et al (2010) Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol. doi:10.​1007/​s00270-009-9781-6
57.
Yoo KM, Yoo BG, Kim KS et al (2004) Cerebral lipiodol embolism during transcatheter arterial chemoembolization. Neurology 63:181–183PubMed
58.
Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (Baltimore) 27:1578–1583
59.
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739CrossRefPubMed
60.
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed
61.
Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469CrossRefPubMed
62.
Hong K, Liapi E, Georgiades CS, Geschwind JF (2005) Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. J Vasc Interv Radiol 16:339–345PubMed
63.
Liapi E, Geschwind JF (2007) Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 25:978–986CrossRefPubMed
64.
Liapi E, Lee KH, Georgiades CC et al (2007) Drug-eluting particles for interventional pharmacology. Tech Vasc Interv Radiol 10:261–269CrossRefPubMed
65.
Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602CrossRefPubMed
66.
Vogl TJ, Gruber T, Naguib NN et al (2009) Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol 193:941–947CrossRefPubMed
67.
Vogl TJ, Naguib NN, Zangos S et al (2009) Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 72:517–528CrossRefPubMed
68.
Tellez C, Benson AB III, Lyster MT et al (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82:1250–1259CrossRefPubMed
69.
Geschwind J, Hong K, Georgiades C (2006) Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting. In: American Society of Clinical Oncology gastrointestinal cancers symposium, San Francisco, CA, 26–28 January 2006
70.
Giroux MF, Baum RA, Soulen MC (2004) Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 15:289–291PubMed
71.
Rajan DK, Soulen MC, Clark TW et al (2001) Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 12(2):187–193CrossRefPubMed
72.
Lee KH, Liapi E, Ventura VP et al (2008) Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. J Vasc Interv Radiol 19:1065–1069CrossRefPubMed
73.
Saluzzo CM, Vignali C, Nicolini A et al (2007) TACE with HepaSphere microspheres loaded with chemotherapeutic agent: early experience in Italy of a multi-centre study. In: WCIO 2007, Washington, DC
74.
Grosso M, Vignali C, Quaretti P et al (2008) Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 31:1141–1149CrossRefPubMed
75.
Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54CrossRefPubMed
76.
Yuen MF, Chan AOO, Wong BCY et al (2003) Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 98:1181–1185PubMed
77.
Brown DB, Chapman WC, Cook RD et al (2008) Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol 190:608–615CrossRefPubMed
78.
Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476CrossRefPubMed
Metadaten
Titel
Transcatheter Arterial Chemoembolization for Liver Cancer: Is It Time to Distinguish Conventional from Drug-Eluting Chemoembolization?
verfasst von
Eleni Liapi
Jean-Francois H. Geschwind
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 1/2011
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-010-0012-y

Weitere Artikel der Ausgabe 1/2011

CardioVascular and Interventional Radiology 1/2011 Zur Ausgabe

Technical Note

MR-Guided Freehand Biopsy of Liver Lesions With Fast Continuous Imaging Using a 1.0-T Open MRI Scanner: Experience in 50 Patients

Review/State of the Art

Vascular Access in Children

Laboratory Investigation

Sustained Growth of the Ex Vivo Ablation Zones’ Critical Short Axis Using Gas-cooled Radiofrequency Applicators

Clinical Investigation

Multidetector-Row Computed Tomography in the Evaluation of Transjugular Intrahepatic Portosystemic Shunt Performed with Expanded-Polytetrafluoroethylene-Covered Stent-Graft

Clinical Investigation

CIRSE Vascular Closure Device Registry

Clinical Investigation

Intercostal Artery Supplying Hepatocellular Carcinoma: Demonstration of a Tumor Feeder by C-arm CT and Multidetector Row CT

Neu im Fachgebiet Radiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise